Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | PPARG | P37231 | 7/20 | 0.49 |
| ▸ | F7 | P08709 | 6/20 | 0.49 |
| ▸ | F3 | P13726 | 6/20 | 0.49 |
| ▸ | PPARD | Q03181 | 6/20 | 0.49 |
| ▸ | PPARA | Q07869 | 6/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | RECQL | P46063 | 3/20 | 0.49 |
| ▸ | BLM | P54132 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30457581 | 1.00 | ALDH1A1 (0.49) | ALDH1A1PPARGF7F3PPARD | |
| SCHEMBL30284630 | 1.00 | ALDH1A1 (0.49) | ALDH1A1PPARGF7F3PPARD | |
| SCHEMBL30849137 | 1.00 | ALDH1A1 (0.49) | ALDH1A1PPARGF7F3PPARD | |
| SCHEMBL17685710 | 1.00 | ALDH1A1 (0.49) | ALDH1A1PPARGF7F3PPARD | |
| SCHEMBL17685786 | 1.00 | ALDH1A1 (0.49) | ALDH1A1PPARGF7F3PPARD | |
| SCHEMBL25431443 | 1.00 | ALDH1A1 (0.49) | ALDH1A1PPARGF7F3PPARD | |
| SCHEMBL17685831 | 1.00 | ALDH1A1 (0.49) | ALDH1A1PPARGF7F3PPARD | |
| SCHEMBL17685809 | 1.00 | ALDH1A1 (0.49) | ALDH1A1PPARGF7F3PPARD | |
| SCHEMBL17685788 | 1.00 | ALDH1A1 (0.49) | ALDH1A1PPARGF7F3PPARD | |
| SCHEMBL30284624 | 1.00 | ALDH1A1 (0.49) | ALDH1A1PPARGF7F3PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160106842-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-04-21 | — | — | US | claimed |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250154102-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-05-15 | — | — | US | disclosed |
| US-20250073164-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2025-03-06 | — | — | US | disclosed |
| US-12215068-B2 | Constrained lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240200118-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240182412-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2024-06-06 | — | — | US | disclosed |
| US-20240067598-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2023196931-A1 | CYCLIC LIPIDS AND LIPID NANOPARTICLES (LNP) FOR THE DELIVERY OF NUCLEIC ACIDS OR PEPTIDES FOR USE IN VACCINATING AGAINST INFECTIOUS AGENTS | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-11773061-B2 | Cyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-10-03 | — | — | US | disclosed |
| WO-2023122752-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230202966-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023044333-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023023055-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| EP-3608308-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | Novartis AG (CH) | 2020-02-12 | — | — | EP | disclosed |
| US-10124065-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2018-11-13 | — | — | US | disclosed |
| US-20160106842-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | ALDH1A1 4876/4885PPARG 1075/4885F7 1620/4885 |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | ALDH1A1 3260/4885PPARG 795/4885F7 3146/4885 |
| US-20250073164-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | SGMS1, SGMS2, ABCB4 | ALDH1A1 3146/4885PPARG 2222/4885F7 2377/4885 |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | PLTP, LNPEP, PCTP | ALDH1A1 4885/4885PPARG 2837/4885F7 2304/4885 |
| US-10124065-B2 | Lipids and lipid compositions for the delivery of active agents | LIPA, LPAR1, LPAR4 | ALDH1A1 2488/4885PPARG 1398/4885F7 626/4885 |
| US-12215068-B2 | Constrained lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | ALDH1A1 4876/4885PPARG 1075/4885F7 1620/4885 |
| US-20250154102-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | ALDH1A1 4882/4885PPARG 2631/4885F7 1893/4885 |
| US-11773061-B2 | Cyclic lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | ALDH1A1 4882/4885PPARG 2631/4885F7 1893/4885 |
| US-20240182412-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | ALDH1A1 4882/4885PPARG 2631/4885F7 1893/4885 |
| US-20240200118-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | NSUN3, PHAX, RNGTT | ALDH1A1 4735/4885PPARG 3770/4885F7 2820/4885 |
| US-20240067598-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | ALDH1A1 4876/4885PPARG 1075/4885F7 1620/4885 |
| US-20160106842-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, LPAR1, LPAR4 | ALDH1A1 2488/4885PPARG 1398/4885F7 626/4885 |
| US-20230202966-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, ABHD16A | ALDH1A1 4878/4885PPARG 2592/4885F7 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.